Literature DB >> 28057386

Nanoparticles decorated with viral antigens are more immunogenic at low surface density.

Matthew G Brewer1, Anthony DiPiazza2, Joshua Acklin1, Changyong Feng3, Andrea J Sant2, Stephen Dewhurst4.   

Abstract

There is an urgent need to develop protective vaccines for high priority viral pathogens. One approach known to enhance immune responses to viral proteins is to display them on a nanoparticle (NP) scaffold. However, little is known about the effect of protein density on the B cell response to antigens displayed on NPs. To address this question HIV-1 Envelope (Env) and influenza hemagglutinin (HA) were displayed on a polystyrene-based NP scaffold at various densities - corresponding to mean antigen distances that span the range encountered on naturally occurring virions. Our studies revealed that NPs displaying lower densities of Env or HA more efficiently stimulated antigen-specific B cells in vitro, as measured by calcium flux, than did NPs displaying higher antigen densities. Similarly, NPs displaying a low density of Env or HA also elicited higher titers of antigen-specific serum IgG in immunized BALB/c mice (including elevated titers of hemagglutination-inhibiting antibodies), as well as an increased frequency of antigen-specific antibody secreting cells in the lymph node, spleen and bone marrow. Importantly, our studies showed that the enhanced B cell response elicited by the lower density NPs is likely secondary to more efficient development of follicular helper CD4 T cells and germinal center B cells. These findings demonstrate that the density of antigen on a NP scaffold is a critical determinant of the humoral immune response elicited, and that high density display does not always result in an optimal response.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antigen density; Antigen display; Envelope; HIV; Hemagglutinin; Humoral immunity; Influenza; Nanoparticle

Mesh:

Substances:

Year:  2017        PMID: 28057386      PMCID: PMC5876043          DOI: 10.1016/j.vaccine.2016.12.049

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  36 in total

1.  An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow.

Authors:  M B Lutz; N Kukutsch; A L Ogilvie; S Rössner; F Koch; N Romani; G Schuler
Journal:  J Immunol Methods       Date:  1999-02-01       Impact factor: 2.303

2.  Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10.

Authors:  Joshua S Klein; Priyanthi N P Gnanapragasam; Rachel P Galimidi; Christopher P Foglesong; Anthony P West; Pamela J Bjorkman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-16       Impact factor: 11.205

3.  The extent of affinity maturation differs between the memory and antibody-forming cell compartments in the primary immune response.

Authors:  K G Smith; A Light; G J Nossal; D M Tarlinton
Journal:  EMBO J       Date:  1997-06-02       Impact factor: 11.598

4.  Studies on the immunogenicity and tolerogenicity of T-independent antigens.

Authors:  R Z Dintzis; M H Middleton; H M Dintzis
Journal:  J Immunol       Date:  1983-11       Impact factor: 5.422

5.  Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.

Authors:  Punnee Pitisuttithum; Peter Gilbert; Marc Gurwith; William Heyward; Michael Martin; Fritz van Griensven; Dale Hu; Jordan W Tappero; Kachit Choopanya
Journal:  J Infect Dis       Date:  2006-11-03       Impact factor: 5.226

6.  Anti-HIV B Cell lines as candidate vaccine biosensors.

Authors:  Takayuki Ota; Colleen Doyle-Cooper; Anthony B Cooper; Michael Huber; Emilia Falkowska; Katherine J Doores; Lars Hangartner; Khoa Le; Devin Sok; Joseph Jardine; Jeffrey Lifson; Xueling Wu; John R Mascola; Pascal Poignard; James M Binley; Bimal K Chakrabarti; William R Schief; Richard T Wyatt; Dennis R Burton; David Nemazee
Journal:  J Immunol       Date:  2012-10-12       Impact factor: 5.422

7.  Development of a nanoparticle-based influenza vaccine using the PRINT technology.

Authors:  Ashley L Galloway; Andrew Murphy; Joseph M DeSimone; Jie Di; Jennifer P Herrmann; Michael E Hunter; Jeffrey P Kindig; Frank J Malinoski; Megan A Rumley; Daria M Stoltz; Thomas S Templeman; Bolyn Hubby
Journal:  Nanomedicine       Date:  2012-11-22       Impact factor: 5.307

Review 8.  Soluble host defense lectins in innate immunity to influenza virus.

Authors:  Wy Ching Ng; Michelle D Tate; Andrew G Brooks; Patrick C Reading
Journal:  J Biomed Biotechnol       Date:  2012-05-16

Review 9.  Playing hide and seek: how glycosylation of the influenza virus hemagglutinin can modulate the immune response to infection.

Authors:  Michelle D Tate; Emma R Job; Yi-Mo Deng; Vithiagaran Gunalan; Sebastian Maurer-Stroh; Patrick C Reading
Journal:  Viruses       Date:  2014-03-14       Impact factor: 5.048

10.  Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity.

Authors:  Kwinten Sliepen; Gabriel Ozorowski; Judith A Burger; Thijs van Montfort; Melissa Stunnenberg; Celia LaBranche; David C Montefiori; John P Moore; Andrew B Ward; Rogier W Sanders
Journal:  Retrovirology       Date:  2015-09-26       Impact factor: 4.602

View more
  7 in total

1.  Influences of nanocarrier morphology on therapeutic immunomodulation.

Authors:  Molly Frey; Sharan Bobbala; Nicholas Karabin; Evan Scott
Journal:  Nanomedicine (Lond)       Date:  2018-08-07       Impact factor: 5.307

2.  Protein Vaccination Directs the CD4+ T Cell Response toward Shared Protective Epitopes That Can Be Recalled after Influenza Virus Infection.

Authors:  Ajitanuj Rattan; Katherine A Richards; Zackery A G Knowlden; Andrea J Sant
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

3.  A Novel Vaccine Strategy to Overcome Poor Immunogenicity of Avian Influenza Vaccines through Mobilization of Memory CD4 T Cells Established by Seasonal Influenza.

Authors:  Anthony T DiPiazza; Shufang Fan; Ajitanuj Rattan; Marta L DeDiego; Francisco Chaves; Gabriele Neumann; Yoshihiro Kawaoka; Andrea J Sant
Journal:  J Immunol       Date:  2019-08-09       Impact factor: 5.422

4.  Immunopotentiation by Lymph-Node Targeting of a Malaria Transmission-Blocking Nanovaccine.

Authors:  Gregory P Howard; Nicole G Bender; Prachi Khare; Borja López-Gutiérrez; Vincent Nyasembe; William J Weiss; Jerry W Simecka; Timothy Hamerly; Hai-Quan Mao; Rhoel R Dinglasan
Journal:  Front Immunol       Date:  2021-08-27       Impact factor: 8.786

Review 5.  Lipid-Based Particles: Versatile Delivery Systems for Mucosal Vaccination against Infection.

Authors:  Blaise Corthésy; Gilles Bioley
Journal:  Front Immunol       Date:  2018-03-07       Impact factor: 7.561

6.  Display of the HIV envelope protein at the yeast cell surface for immunogen development.

Authors:  Elizabeth Mathew; Hong Zhu; Sara M Connelly; Mark A Sullivan; Matthew G Brewer; Michael S Piepenbrink; James J Kobie; Stephen Dewhurst; Mark E Dumont
Journal:  PLoS One       Date:  2018-10-18       Impact factor: 3.240

Review 7.  Advantages and Prospects of Tag/Catcher Mediated Antigen Display on Capsid-Like Particle-Based Vaccines.

Authors:  Kara-Lee Aves; Louise Goksøyr; Adam F Sander
Journal:  Viruses       Date:  2020-02-06       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.